-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

509 TBI-Based Myeloablative Conditioning Two-Step Haploidentical Allogeneic Hematopoietic Stem Cell Transplant Yields Excellent Outcomes in Fit Patients with High-Risk Hematologic Malignancies, Results of a Prospective Trial

Program: Oral and Poster Abstracts
Type: Oral
Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Optimizing Conditioning and Donor Selection in Allogeneic Stem Cell Transplantation
Hematology Disease Topics & Pathways:
Research, Clinical trials, Clinical Research
Sunday, December 8, 2024: 10:30 AM

Boula Gattas, MD1*, Xia Bi, MD2*, Dolores Grosso, DNP1*, Alicia Bao, MD3*, Allison Gradone, MD1*, Brenda Grande1*, Gina Mateja1*, Arpona Dev Nath, MD4*, Joanne Filicko-O'Hara, MD2, William O'Hara, PharmD1*, John Wagner, MD1*, Neal Flomenberg, MD1* and Usama Gergis, MD, MBA2

1Thomas Jefferson University, Philadelphia
2Department of Bone Marrow Transplant and Cellular Therapy, Sidney Kimmel Cancer Center of Thomas Jefferson University, Philadelphia, PA
3Thomas Jefferson University, Philadelphia, PA
4Thomas Jefferson University Hospital, Philadelphia, PA

Background: Since 2005, Thomas Jefferson University has developed the two-step allogeneic hematopoietic stem cell transplant (HSCT) approach that isolates the graft's lymphoid and myeloid components. The two-step platform allows for a consistent T cell dosage and shields the stem cells from the effects of cyclophosphamide. We previously reported promising outcomes and an acceptable safety profile. In this prospective study, we investigated a novel TBI-based myeloablative conditioning (MAC) prior to two-step HSCT for fit patients with high-risk hematologic malignancies. Methods: From 2017-2023, forty-six patients received 12 Gy TBI, prior to receiving 2 x 10*8 /kg DLI. Two days later, patients received cyclophosphamide 60 mg/kg/day x 2. Finally, patients received CD34- selected stem cell grafts. Patients received MMF and tacrolimus for GVHD prophylaxis. Results: The median age was 55.5 years old (range 23-65 years). Thirty-six patients (78%) identified as Caucasian and 48% female. The most common diagnosis was Acute Myeloid Leukemia, (n=25, 54%), followed by Myelodysplastic Syndromes (n=8, 17%), and Acute Lymphoblastic Leukemia (n=6, 13%). The median HCT-CI score was 3 (range, 0-7), while 10 patients (22%) had a high disease risk index. The vast majority of patients received a haploidentical (HI) stem cell graft (n=44, 96%) All patients achieved neutrophil engraftment at a median of 11 days (range 9-19) and platelet engraftment at a median of 15 days (range 12-23). After a median follow up of 23 months (range, 0-67), the Overall survival (OS) and progression-free survival (PFS) were 68% (95%CI 56% - 84%) at one year and 65% (95%CI 53% - 81%) and 60% (47% - 77%) respectively at 5 years. The cumulative incidence of non-relapse mortality (NRM) and relapse were 20% and 12% at one year and 20% and 14% at 5 years. There was a total of 15 (33%) deaths: 4 patients succumbed to toxicity, 5 to infections, and 6 to primary disease relapse. GVHD-free, relapse-free survival (GRFS) was assessed by the absence of grade III-IV acute GVHD or chronic GVHD requiring systemic treatment, with GRFS rates of 62% at one year (95% CI: 49%-78%) and 54% at 5 years (95% CI: 41%-71%). The cumulative incidence (CI) of acute grade II-IV GVHD was 27% at 100 days and 33% at 200 days, while the CI of acute grade III GVHD was 2.4% at 200 days. Chronic GVHD had a CI of 14% at both 1 year and 5 years. There were no instances of grade IV acute GVHD, severe chronic GVHD, or deaths attributable to GVHD. Patients undergoing HSCT while in remission (n=36, 78%) experienced significantly better survival rates compared to those with active disease (1-year OS 76% vs 40%, 5-year OS 76% vs 27%, p = 0.0029). Conclusion: The TBI-based myeloablative conditioning Two-Step HI HSCT yields Excellent Outcomes in Fit Patients with High-Risk Hematologic Malignancies. Despite the use of HI peripheral stem cell grafts, there were no grade IV aGVHD, severe cGVHD or GVHD related deaths.

Disclosures: Grosso: Tevogen Bio: Current Employment. Flomenberg: Tevogen Bio: Current Employment. Gergis: Moderna: Current equity holder in publicly-traded company; Iovance: Current equity holder in publicly-traded company; Kite: Other: Travel Support, Speakers Bureau; Astellas: Other: Travel Support, Speakers Bureau; Autolus: Consultancy; Incyte: Other: Travel Support, Speakers Bureau; VOR: Consultancy; Biontech: Current equity holder in publicly-traded company; Jazz: Other: Travel Support, Speakers Bureau.

*signifies non-member of ASH